Insmed Incorporated (NASDAQ:INSM) Insider Martina M.D. Flammer Sells 6,172 Shares

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 6,172 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $63.64, for a total value of $392,786.08. Following the completion of the sale, the insider now directly owns 101,549 shares of the company’s stock, valued at approximately $6,462,578.36. This represents a 5.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Martina M.D. Flammer also recently made the following trade(s):

• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The shares were sold at an average price of $65.91, for a total value of $220,403.04.

Insmed Trading Down 0.7 %

Shares of INSM stock opened at $65.25 on Friday. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The company has a market cap of $11.67 billion, a PE ratio of -11.76 and a beta of 1.12. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The business’s 50 day moving average is $71.23 and its two-hundred day moving average is $72.42.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.10) EPS. Equities analysts predict that Insmed Incorporated will post -5.44 EPS for the current year.

Hedge Funds Weigh In On Insmed

A number of institutional investors have recently made changes to their positions in the business. V Square Quantitative Management LLC bought a new stake in Insmed during the 3rd quarter valued at approximately $30,000. GAMMA Investing LLC lifted its holdings in shares of Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 224 shares during the last quarter. Exchange Traded Concepts LLC boosted its position in shares of Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 627 shares during the period. Blue Trust Inc. grew its stake in shares of Insmed by 2,348.8% in the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 1,879 shares during the last quarter. Finally, JCIC Asset Management Inc. bought a new position in Insmed during the third quarter worth $133,000.

Analysts Set New Price Targets

INSM has been the topic of a number of research analyst reports. Bank of America boosted their price objective on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. JPMorgan Chase & Co. lifted their price objective on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research report on Friday, November 22nd. Finally, Truist Financial reaffirmed a “buy” rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.